Profound Medical Corp. Common Stock
PROFProfound Medical Corp. is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of various urological conditions. It specializes in minimally invasive, image-guided treatments, notably through its flagship platform for transurethral ultrasound-guided therapy. The company aims to provide effective and less invasive procedures that improve patient outcomes in areas such as benign prostatic hyperplasia (BPH).
Company News
The global AI in medical imaging market is experiencing rapid growth with a projected $2.20 billion valuation in 2026 and 34.8% CAGR through 2033. Major medtech companies including Danaher, Medtronic, DexCom, and Profound Medical are making strategic acquisitions and expanding AI-powered diagnostic platforms. Hospitals are increasingly prioritizi...
The Portnoy Law Firm has initiated an investigation into Profound Medical Corp. for possible securities fraud after the company disclosed a $472,000 revenue overstatement in Q1 2024. The error affected financial statements across multiple quarters, prompting a restatement and causing the stock to fall 5.9% to $6.86 per share on March 7, 2025. Inv...
Profound Medical Corp. successfully closed a $36 million registered direct offering of 5.14 million common shares at $7.00 per share. The company plans to use net proceeds for sales and marketing expansion, working capital, R&D, and strategic transactions. An additional $4 million private placement with Canadian purchasers is expected to close by...
Dr. Pejman Ghanouni from Stanford Medicine received a Cum Laude award at RSNA 2025 for presenting results from the CAPTAIN trial, comparing MRI-guided transurethral ultrasound ablation (TULSA) with robotic radical prostatectomy for prostate cancer treatment.
AI platform Profound has been recognized by Redpoint Ventures in their inaugural AI64 list, highlighting the company's innovative approach to AI-powered brand visibility and marketing optimization.
